149 related articles for article (PubMed ID: 8520812)
1. Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade.
Bashaw ED; Kaiko RF; Grandy RP; Reder RF; Goldenheim PD
Int J Clin Pharmacol Ther; 1995 Sep; 33(9):524-9. PubMed ID: 8520812
[TBL] [Abstract][Full Text] [Related]
2. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
[TBL] [Abstract][Full Text] [Related]
3. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
[TBL] [Abstract][Full Text] [Related]
4. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
Setnik B; Sommerville K; Goli V; Han L; Webster L
Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
6. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
[TBL] [Abstract][Full Text] [Related]
7. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
[TBL] [Abstract][Full Text] [Related]
8. The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets.
Kaiko RF; Fitzmartin RD; Thomas GB; Goldenheim PD
Pharmacotherapy; 1992; 12(2):107-13. PubMed ID: 1570227
[TBL] [Abstract][Full Text] [Related]
9. [Bioavailability of morphine after oral administration as retard tablets].
Dittrich P; Semmelrock J; Wolf G; Beubler E
Wien Klin Wochenschr; 1996; 108(5):147-52. PubMed ID: 8901129
[TBL] [Abstract][Full Text] [Related]
10. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
11. Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Johnson F; Ciric S; Boudriau S; Swearingen D; Stauffer J
Adv Ther; 2010 Nov; 27(11):846-58. PubMed ID: 20949341
[TBL] [Abstract][Full Text] [Related]
12. A bioequivalence study of oral controlled-release morphine using naltrexone blockade.
Kaiko RF; Grandy RP; Reder RF; Goldenheim PD; Sackler RS
J Clin Pharmacol; 1995 May; 35(5):499-504. PubMed ID: 7657850
[TBL] [Abstract][Full Text] [Related]
13. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
Johnson F; Setnik B
Pain Physician; 2011; 14(4):391-406. PubMed ID: 21785483
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oral morphine sulfate in dogs: a comparison of sustained release and conventional formulations.
Dohoo SE; Tasker RA
Can J Vet Res; 1997 Oct; 61(4):251-5. PubMed ID: 9342447
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
Setnik B; Roland CL; Goli V; Sommerville K; Webster L
J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetic profiles of two oral controlled-release morphine formulations in healthy young adults.
Hunt TL; Kaiko RF
Clin Ther; 1991; 13(4):482-8. PubMed ID: 1934000
[TBL] [Abstract][Full Text] [Related]
17. Comparative bioavailability cf two amlodipine formulation in healthy volunteers.
Setiawati E; Sukmayadi ; Yunaidi DA; Handayani LR; Harinanto G; Santoso ID; Deniati SH
Arzneimittelforschung; 2007; 57(7):467-71. PubMed ID: 17803060
[TBL] [Abstract][Full Text] [Related]
18. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
[TBL] [Abstract][Full Text] [Related]
19. Relative bioavailability of different butamirate citrate preparations after single dose oral administration to 18 healthy volunteers.
Bohner H; Janiak PS; Nitsche V; Eichinger A; Schütz H
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):117-22. PubMed ID: 9089001
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
Webster LR; Brewer R; Wang C; Sekora D; Johnson FK; Morris D; Stauffer J
J Pain Symptom Manage; 2010 Nov; 40(5):734-46. PubMed ID: 21075272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
